Abbott Laboratories said Wednesday that it plans to split into two publicly traded companies, separating its medical products business from its research-based pharmaceuticals operations.
Also Read | Indian arm to come under medical biz
The medical-products company will consist of Abbott’s generic-pharmaceutical, devices, diagnostic and nutritional businesses, and will keep the Abbott name. The research-based pharmaceutical company will include Abbott’s portfolio of pharmaceuticals and biologics and will be named later.
File photo Bloomberg
To read the full story (Click here )